Project Grant HT94252510728
Award Date 10/1/25
Completion Date 9/30/27
Dollars Obligated $712K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
- The federal Project Grant award of $2,136,000 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, Massachusetts. The award, with a performance period from May 1, 2025 to April 30, 2028, is focused on "Reversibility and Therapeutic Targeting of Treatment-Emergent Neuroendocrine Prostate Cancer." Dfci, a renowned nonprofit cancer research and treatment center, will...
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
- The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $947,746 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on "IDENTIFICATION OF THE LIVER MICROENVIRONMENT THAT DRIVES UVEAL MELANOMA METASTASIS AND IMMUNITY". The 3-year grant, beginning on September 1, 2024 and ending on August 31, 2027, will enable DFCI, a non-profit cancer research center in Boston, MA, to investigate the liver...
- The U.S. Department of Defense (Defense Health Agency) awarded a $1,424,000.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The grant, titled "EXPANDING THE TARGETABLE TUMOR ANTIGEN REPERTOIRE OF RENAL CELL CARCINOMA", will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The 4-year project,...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
- The Defense Health Agency awarded a $524,664 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) through the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, which runs from December 1, 2024 to November 30, 2026, will fund research into the "Mechanisms of Irisin-Induced Cognitive Benefit in PD." DFCI, a prestigious non-profit cancer research center in Boston, will leverage its expertise in areas like oncology, immunology, and...